“Intranasal naloxone is safe and effective for reversing opioid overdose and is now available without prescription,” authors of a JAMA Insights article conclude. “Physicians and
“Xylazine pharmacology, animal and human clinical effects, and what is known to date about care of patients experiencing acute overdose, xylazine–fentanyl withdrawal, and xylazine-associated wounds”
Out-of-hospital therapeutic errors involving medications for attention-deficit/hyperactivity disorder (ADHD) reported to U.S. poison control centers rose by nearly 300% between 2000 and 2021, researchers report.
In a phase 2 trial of adults aged 21 to 65 years with major depressive disorder (MDD), treatment with psilocybin “was associated with a clinically
The FDA is exploring ways it can regulate CBD in foods and supplements, the Wall Street Journal reports. “The FDA has approved a drug named
The FDA and the National Institute of Standards and Technology are collaborating on a project to develop and harmonize methods to standardize the description of the temperature
Updated and expanded recommendations for clinicians providing pain care for adult outpatients with short- and long-term pain were released yesterday by the CDC. Published in
The shortage of the immediate-release formulation of amphetamine mixed salts (Adderall or Adderall IR) announced earlier this month by FDA has the potential to lead
The recent U.S. Supreme Court decision in the Ruan v United States case narrows the risk physicians face as a result of their prescribing practices,